[1] Sung H, Ferlay J, Siegel R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] Heimbach J K, Kulik L M, Finn R S, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J].Hepatology,2018,67(1):358-380.
[3] Gentile D, Donadon M, Lleo A, et al. Surgical treatment of hepatocholangiocarcinoma: a systematic review[J]. Liver Cancer, 2020,9(1):15-27.
[4] Chen W, Zheng R, Baade P D ,et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[5] Llovet J M, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
[6] Cheng A L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J].Hepatology,2022,76(4):862-873.
[7] Sun L, Bleiberg B, Hwang W T, et al. Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer[J].JAMA Oncol,2023,9(8):1075-1082.
[8] Robert C, Marabelle A, Herrscher H, et al. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm[J].Nat Rev Clin Oncol, 2020,17(11):707-715.
[9] Yan W T, Li C, Yao L Q, et al. Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study[J].Hepatobiliary Surg Nutr,2023,12(2):155-168.
[10] Nevola R, Ruocco R, Criscuolo L, et al. Predictors of early and late hepatocellular carcinoma recurrence[J].World J Gastroenterol,2023,29(8):1243-1260.
[11] Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J].Lancet Oncol,2015,16(13):1344-1354.
[12] Qin S, Chen M, Cheng A L, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023,402(10415):1835-1847.
[13] Yopp A, Kudo M, Chen M. et al. LBA39 Updated efficacy and safety data from IMbrave050: phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)[J]. Annals of Oncology, Volume 35, S1230.
[14] Ho W J, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity[J]. Nat Cancer, 2021,2(9):891-903.
[15] Llovet J M, Pinyol R, Yarchoan M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2024,21(4):294-311.
[16] Singal A G, Yarchoan M, Yopp A, et al. Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future[J]. Hepatol Commun, 2024,8(6):e0430.
[17] Liu J, Blake S J, Yong M C, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease[J]. Cancer Discov, 2016,6(12):1382-1399.
[18] Marron T U, Fiel M I, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022,7(3):219-229.
[19] Tian C, Yu Y, Wang Y, et al. Neoadjuvant immune checkpoint inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review[J]. Front Immunol, 2024,15:1352873.
[20] D′Alessio A, Stefanini B, Blanter J, et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis[J]. Lancet Oncol, 2024,25(11):1465-1475.
[21] Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial[J]. J Immunother Cancer, 2022,10(4):e004656.
[22] Kaseb A O, Hasanov E, Cao H S T, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022,7(3):208-218.
[23] Zhu C, Zhang C, Wang S, et al. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma[J]. J Immunother Cancer, 2024,12(6):e008686.
[24] Zhou C, Weng J, Liu C, et al. Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma[J]. Gastroenterology, 2023,164(7):1261-1278.
[25] Hsu C L, Ou D L, Bai L Y, et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma[J]. Liver Cancer, 2021,10(4):346-359.
[26] Dai S, Chen Y, Cai W, et al. Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy[J]. J Hematol Oncol, 2025,18(1):85. |
